NCT04848662View on ClinicalTrials.gov

To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 6, 2021

Primary Completion Date

July 5, 2021

Study Completion Date

July 8, 2021

Conditions
Asthma
Interventions
DRUG

BDA MDI (PT027) 160/180 μg

Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/90 μg per puff. Two puffs to administer 160/180 μg dose.

DRUG

Pulmicort Respules 0.5 MG/ML Inhalation Suspension

Budesonide 0.5 mg/ml. Each 2 ml Respule contains 1 mg budesonide.

Trial Locations (2)

73106

IPS Research, Oklahoma City

78006

TTS Research, Boerne

All Listed Sponsors
lead

Bond Avillion 2 Development LP

INDUSTRY